EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 30 / No 1 (Janvier 2014) Med Sci (Paris), 30 1 (2014) 69-75 References
Free Access
Issue
Med Sci (Paris)
Volume 30, Number 1, Janvier 2014
Page(s) 69 - 75
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20143001016
Published online 24 January 2014
  1. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012 ; 366 : 1275–1286. [CrossRef] [PubMed] [Google Scholar]
  2. Tomaras GD, Ferrari G, Shen X, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci USA 2013 ; 110 : 9019–9024. [CrossRef] [Google Scholar]
  3. McMichael AJ, Haynes BF. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol 2012 ; 13 : 423–427. [CrossRef] [PubMed] [Google Scholar]
  4. Montefiori DC, Karnasuta C, Huang Y, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012 ; 206 : 431–441. [CrossRef] [PubMed] [Google Scholar]
  5. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010 ; 28 : 413–444. [CrossRef] [PubMed] [Google Scholar]
  6. Moog C, Fleury HJ, Pellegrin I, et al. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997 ; 71 : 3734–3741. [PubMed] [Google Scholar]
  7. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011 ; 477 : 466–470. [CrossRef] [PubMed] [Google Scholar]
  8. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009 ; 458 : 636–640. [CrossRef] [PubMed] [Google Scholar]
  9. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012 ; 37 : 412–425. [CrossRef] [PubMed] [Google Scholar]
  10. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000 ; 6 : 207–210. [CrossRef] [PubMed] [Google Scholar]
  11. Hessell AJ, Poignard P, Hunter M, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009 ; 15 : 951–954. [CrossRef] [PubMed] [Google Scholar]
  12. Holl V, Peressin M, Decoville T, et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006 ; 80 : 6177–6181. [CrossRef] [PubMed] [Google Scholar]
  13. Holl V, Peressin M, Schmidt S, et al. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 2006 ; 107 : 4466–4474. [CrossRef] [PubMed] [Google Scholar]
  14. Peressin M, Holl V, Schmidt S, et al. HIV-1 replication in Langerhans and interstitial dendritic cells is inhibited by neutralizing and Fc-mediated inhibitory antibodies. J Virol 2011 ; 85 : 1077–1085. [CrossRef] [PubMed] [Google Scholar]
  15. Moody MA, Liao HX, Alam SM, et al. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med 2010 ; 207 : 763–776. [CrossRef] [PubMed] [Google Scholar]
  16. Su B, Xu K, Lederle A, et al. Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T-lymphocytes. Blood 2012 ; 120 : 3708–3717. [CrossRef] [PubMed] [Google Scholar]
  17. Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007 ; 262 : 5–25. [CrossRef] [PubMed] [Google Scholar]
  18. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007 ; 449 : 101–104. [CrossRef] [PubMed] [Google Scholar]
  19. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 2011 ; 108 : 11181–11186. [CrossRef] [Google Scholar]
  20. Moog C, Dereuddre-Bosquet N, Teillaud JL, et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol 2013 ; doi : 10.1038/mi.2013.23. [Google Scholar]
  21. Connick E, Marr DG, Zhang XQ, et al. HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res Hum Retrovir 1996 ; 12 : 1129–1140. [CrossRef] [Google Scholar]
  22. Holl V, Hemmerter S, Burrer R, et al. Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J Immunol 2004 ; 173 : 6274–6283. [PubMed] [Google Scholar]
  23. Lambotte O. Les patients HIV controllers. Med Sci (Paris) 2012 ; 28 : 172–178. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  24. Mestecky J, Jackson S, Moldoveanu Z, et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retrovir 2004 ; 20 : 972–988. [CrossRef] [Google Scholar]
  25. Broliden K, Hinkula J, Devito C, et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett 2001 ; 79 : 29–36. [CrossRef] [PubMed] [Google Scholar]
  26. Mantis NJ, Palaia J, Hessell AJ, et al. Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region. J Immunol 2007 ; 179 : 3144–3152. [PubMed] [Google Scholar]
  27. Stieh G, McRaven M, Cianci G, et al. Development of an imaging based virus aggregation assay for vaccine development. Retrovirology 2012 ; 9 : 319. [CrossRef] [Google Scholar]
  28. Watkins JD, Sholukh AM, Mukhtar MM, et al. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 2013 ; 27 : F13–F20. [CrossRef] [PubMed] [Google Scholar]
  29. Laurence J, Saunders A, Early E, Salmon JE. Human immunodeficiency virus infection of monocytes: relationship to Fc-gamma receptors and antibody-dependent viral enhancement. Immunology 1990 ; 70 : 338–343. [PubMed] [Google Scholar]
  30. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 2003 ; 13 : 387–398. [CrossRef] [PubMed] [Google Scholar]
  31. Forthal DN, Gabriel EE, Wang A, et al. Association of Fcgamma receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood 2012 ; 120 : 2836–2842. [CrossRef] [PubMed] [Google Scholar]
  32. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012 ; 30 : 423–433. [CrossRef] [PubMed] [Google Scholar]
  33. Moldt B, Schultz N, Dunlop DC, et al. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcgamma receptors to define the role of effector functions in protection against HIV. J Virol 2011 ; 85 : 10572–10581. [CrossRef] [PubMed] [Google Scholar]
  34. Moldt B, Shibata-Koyama M, Rakasz EG, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012 ; 86 : 6189–6196. [CrossRef] [PubMed] [Google Scholar]
  35. Ruffin N, Borggren M, Euler Z, et al. Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011. J Transl Med 2012 ; 10 : 144. [CrossRef] [PubMed] [Google Scholar]
  36. PX’Therapeutics. PX’Therapeutics annonce l’essai clinique EuroNeut-41 portant sur un vaccin prophylactique contre le VIH. Business Wire 2012 ; 12 mars. [Google Scholar]
  37. Ng CT, Jaworski JP, Jayaraman P, et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 2010 ; 16 : 1117–1119. [CrossRef] [PubMed] [Google Scholar]
  38. Michaud HA, Gomard T, Gros L, et al. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog 2010 ; 6 : e1000948. [CrossRef] [PubMed] [Google Scholar]
  39. Abes R, Gelize E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010 ; 116 : 926–934. [CrossRef] [PubMed] [Google Scholar]
  40. Schwartz C, Le Douce V, Cherrier T, et al. Un virus tapi dans l’ombre : les bases moléculaires de la latence du VIH-1. Med Sci (Paris) 2010 ; 26 : 159–164. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  41. Le Tortorec A, Dejucq-Rainsford N. Le tractus génital masculin. Med Sci (Paris) 2010 ; 26 : 861–868. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  42. Abès R, Dutertre CA, Teillaud JL. Les anticorps : mieux les connaître pour mieux s’en servir. Med Sci (Paris) 2009 ; 25 : 1011–1019. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  43. Deligne C, Teillaud JL. Le double visage des anticorps monoclonaux en oncologie. Med Sci (Paris) 2013 ; 29 : 57–63. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.